$PPBT mkt cap 78M Fair value right now is 120-150M after prelim data which we already had. 1.2M short shares were used to hold us down. Days to cover is now 13 Fair value post phase 1 data on both drugs? 250M+ If data is insanely good we are looking at 350M+ That’s 19.8 per share. We are at a cross rods with the Jeffries presentation and Consensi settlement coming up. Our assets have mkt cap added value of only about 8-9M each. Congrats, you found the bottom 7 trial sites up and running for nt219 in phase 1 4 up and running for cm-24 opdivo Prelim data was great on both.